Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 3(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00336544Phase 3Completed

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia

Role: lead

NCT00336505Phase 3Completed

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)

Role: lead

NCT00701987Phase 1Unknown

Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

Role: lead

All 3 trials loaded